Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Patients who have undergone cardiac ablation will be randomized and blinded to one of two
groups; one group will receive dronedarone while the other group will receive a placebo. The
incidence of atrial fibrillation recurrence, as well as atrial fibrosis progression, will be
analyzed between the two trial groups.
Phase:
Phase 4
Details
Lead Sponsor:
Tulane University School of Medicine
Collaborators:
Cardiac Designs Inc. Marrek, INC Preventice Sanofi University of Washington